The Latest Breaking News from Abbott Laboratories

These three Dividend Kings have strong cash flow and EPS growth, making a compelling case for long-term income investors.

These three dividend stocks easily beat the S&P 500's return in 2025 while offering predictable earnings and dividend growth.

Markets rise on improving geopolitical sentiment, leaving some quality dividend stocks to remain oversold.

As Abbott Laboratories has outperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

These three Dividend Kings are beating the market in 2025, offering strong yields, reliable growth, and solid analyst buy ratings.

Abbott Laboratories stock price is on track to hit a new high in 2025 and could do it before the end of the first half. Dividends and buybacks help.

The S&P 500 Index ($SPX ) (SPY ) today is down -2.38%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.55%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -3.29%. June E-mini S&P futures (ESM25 ) are down -2.16%, and June E-mini Nasdaq futures...

Abbott Laboratories is expected to announce its first-quarter results this month, and analysts predict a single-digit growth in the company’s bottom-line figure.

Abbott Laboratories has notably outpaced the Dow Jones Industrial Average over the past year and analysts remain strongly bullish on the stock’s prospects.

Abbott Laboratories has underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.

The healthcare industry is poised for growth driven by aging populations, technological advancements, and increased healthcare spending. Hence, investors might consider investing in healthcare stocks, such as UnitedHealth Group (UNH), Abbott Laboratories (ABT), and Medtronic (MDT), which address the needs of the aging population. Read more….